This study is part of the study with title "Monitoring drug resistance in subjects with P. falciparum and P.vivax malaria in Kalimantan and Sulawesi, Indonesia" which the objective to assess the efficacy and safety of Dihydroartemisinin - Piperaquine (DHP) in patients with malaria vivax in Kalimantan and Sulawesi. The design of study was a cross-sectional study and prospective evaluation of 87 …
Malaria is still a public health problem in Indonesia. The clinical manifestation of malaria is varied, and many factors may influence its clinical manifestation. Despite the species of malaria, density of parasitemia is known related to the severity or malignancy of malaria. It is worth to analyse the clinical and laboratory data of malaria cases in monitoring dihydroartemisinin-piperaquine (D…
Since 2008, Dihydroartemisinin-Piperaquine (DHP) has been used as the first-line drug for treatment of falciparum malaria in Papua, which gradually will also be used in other endemic areas. The objective of the study was to determine the safety and efficacy of DHP. Patients with uncomplicated malaria due to Plasmodium falciparum were enrolled and treated with supervised DHP (arterakin ®, no. …
The development of DHF patient usually assessed base on clinical condition, platelet count and haematocrit value as the DSS indicators. While leukocyte count is irrespective though leucopenia is common in viral infection. Therefore, further analysis was run to determine whether leucopenia could be as a predictor of DSS This study was a retrospective study with a case control (1:2) design usi…
Background: Clinical and parasitological response of malaria treatment on day 3 follow-up (D3) is a crucial condition to predict the successful of treatment. D3 is a period time that Early Treatment Failure may happen which may cause severe or complicated malaria. Moreover, if the asexual parasitemia is still detected more than 10% study subjects, it is assumed parasites resistance against arte…